The Free T3/Free T4 Ratio Predicts Relapse After Antithyroid Drug Withdrawal in Pediatric Autoimmune Hyperthyroidism
The Journal of Clinical Endocrinology & Metabolism · 13.08.2026 · 111 (9) · e2118-e2126
DOI: 10.1210/clinem/dgag130 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 31.03.2026. Verfasst von Marco Abbate und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Endocrine Unit, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy. Hauptthemen laut MEDLINE: Antithyroid Agents, Thyroxine, Triiodothyronine, Hyperthyroidism. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Context
The likelihood of remission in patients with autoimmune hyperthyroidism (AH) depends on several prognostic factors. The free T3 (FT3)/free T4 (FT4) ratio has been suggested as a potential marker of disease severity and prognosis.
Objective
To evaluate the prognostic value of the FT3/FT4 ratio in predicting the likelihood of relapse in patients with AH.
Methods
This retrospective cohort study included 80 patients with AH diagnosed between 2000 and 2021. Clinical and biochemical data were collected at diagnosis and during follow-up to assess the likelihood of remission in patients attempting to discontinue antithyroid drug (ATD) therapy. Receiver operating characteristic analysis and logistic regression were used to identify predictors of relapse.
Results
Of the 48 patients who discontinued ATD therapy, 24 (50%) relapsed, predominantly within 12 months. The FT3/FT4 ratio was significantly higher in patients who relapsed both at diagnosis (median 0.46 vs 0.36; P .001) and at ATD withdrawal (median 0.43 vs 0.33; P < .001). An FT3/FT4 ratio ≥0.42 at diagnosis predicted relapse with 83% sensitivity and 66% specificity. In a multivariate analysis, FT3/FT4 ratio ≥0.42 at diagnosis (odds ratio 7.18; P .012) and the presence of orbitopathy were identified as independent predictors of relapse. Longer time to FT3 normalization (P .02) and orbitopathy were associated with relapse in univariate analyses (P .039).
Conclusion
The FT3/FT4 ratio, measured both at diagnosis and before ATD withdrawal, is a significant predictor of relapse in AH. This parameter may represent a useful tool for guiding decisions about treatment duration and withdrawal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Endocrine Unit, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.
- Laboratory of Pediatric Endocrinology, Department of Pediatrics, IRCCS Ospedale San Raffaele, Milan 20132, Italy.
- Department of Pediatrics, Endocrine Unit, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.
ORCID-Profile: Stefano Mora, Maria Cristina Vigone
Zitieren
APA
Abbate, M., Vincenzi, G., Mora, S., Tarantola, G., Petralia, I. T., Santagiuliana, C., Del Giacco, L., Zanelli, S., & Vigone, M. C. (2026). The Free T3/Free T4 Ratio Predicts Relapse After Antithyroid Drug Withdrawal in Pediatric Autoimmune Hyperthyroidism. The Journal of Clinical Endocrinology & Metabolism, 111(9), e2118-e2126. https://doi.org/10.1210/clinem/dgag130
Vancouver
Abbate M, Vincenzi G, Mora S, Tarantola G, Petralia IT, Santagiuliana C, et al. The Free T3/Free T4 Ratio Predicts Relapse After Antithyroid Drug Withdrawal in Pediatric Autoimmune Hyperthyroidism. The Journal of Clinical Endocrinology & Metabolism. 2026;111(9):e2118-e2126. doi:10.1210/clinem/dgag130
BibTeX
@article{Abbate2026,
author = {Abbate, Marco and Vincenzi, Gaia and Mora, Stefano and Tarantola, Giulia and Petralia, Ilenia Teresa and Santagiuliana, Cristina and Del Giacco, Luisa and Zanelli, Sara and Vigone, Maria Cristina},
title = {The Free T3/Free T4 Ratio Predicts Relapse After Antithyroid Drug Withdrawal in Pediatric Autoimmune Hyperthyroidism},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {9},
pages = {e2118--e2126},
doi = {10.1210/clinem/dgag130}
}
EUVIMED